BioAge Labs, Inc.

Contributing Author

Recent Articles by BioAge Labs, Inc.

Sep-08	BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema BIOA GlobeNewswire
Sep-02	BioAge Labs to Present at Upcoming Investor Conferences BIOA GlobeNewswire
Aug-05	BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates BIOA GlobeNewswire
Jun-16	BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk BIOA GlobeNewswire
May-22	BioAge Labs to Present at Upcoming Investor Conferences BIOA GlobeNewswire
May-08	BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates BIOA GlobeNewswire
May-04	BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 BIOA GlobeNewswire
Apr-21	BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP BIOA GlobeNewswire
Apr-13	BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference BIOA GlobeNewswire
Mar-24	BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 BIOA -13.53% GlobeNewswire
Feb-19	BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference BIOA GlobeNewswire
Jan-21	BioAge Announces Pricing of Upsized $115.0 Million Public Offering BIOA -6.06% GlobeNewswire
Jan-20	BioAge Announces Proposed Public Offering BIOA +5.75% GlobeNewswire
Jan-20	BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 BIOA +5.75% GlobeNewswire
Jan-12	BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk BIOA +27.23% GlobeNewswire
Dec-04	BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor BIOA +13.88% GlobeNewswire
Nov-25	BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference BIOA GlobeNewswire
Nov-07	BioAge Labs to Present at Jefferies Global Healthcare Conference in London BIOA GlobeNewswire
Nov-06	BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates BIOA GlobeNewswire
Aug-20	BioAge Labs to Present at Upcoming Investor Conferences BIOA GlobeNewswire
Aug-15	BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor BIOA GlobeNewswire
Aug-06	BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates BIOA GlobeNewswire
Jun-21	BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions BIOA GlobeNewswire
Jun-17	BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank BIOA GlobeNewswire
Jun-03	BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates BIOA GlobeNewswire
May-29	BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic BIOA GlobeNewswire
May-27	BioAge Labs to Present at Upcoming Investor Conferences BIOA GlobeNewswire
May-06	BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates BIOA GlobeNewswire

BioAge Labs, Inc.

Recent Articles by BioAge Labs, Inc.

Upgrade your Finviz experience